Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals company Cipla announced Q4FY24 & FY24 results:
FY24 Financial Highlights:
For the fiscal year 2024, Cipla's annual revenue surpassed Rs 25,000 crore with a growth of 14% YoY, while the Profit After Tax (PAT) soared by an impressive 47% YoY to Rs 4,106 crore.
Q4FY24 Financial Highlights:
For Q4FY24, Cipla's revenue was Rs 6,163 crore with a growth of 10% YoY, while the Profit After Tax (PAT) soared by an impressive 79% YoY to Rs 939 crore.
Umang Vohra MD and Global CEO, Cipla, said “I am pleased to share our performance for the year where we made substantial progress across our focused markets. In FY24, our revenues crossed the threshold of Rs 25,000 crore whereas operating margins significantly improved to cross Rs 6,000 crore for very first time, growing at healthy 14% on topline and 26% on profitability YoY. This was backed by One-India revenue breaching Rs 10,000 crore, North America revenue surpassing USD 900 million and South Africa reaching top spot in prescription market, with all three businesses growing in double digits over last year with improved profitability. As we enter into FY25, our focus will be on our priorities of market leading growth in our key markets, growing big brands bigger, investing in future pipeline as well as focusing on resolutions on regulatory front”.
FAQ’s on Cipla Ltd Shares
